Considered together, these data suggest that the significant anti-metastatic effects of genetic or pharmacological targeting of Ezh2 in multiple models reflect a direct requirement for the catalytic activity of Ezh2 in facilitating dissemination of Luminal B breast cancer cells which is independent of the relatively minor effects on the growth of the primary tumour. Here, EZH2 is linked to breast cancer.